Combination treatment of an Anti-CD20 / Anti-CD3 bispecific antibody and chemotherapy

TW202635341APending Publication Date: 2026-09-01F HOFFMANN LA ROCHE & CO AG +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114141863
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-12-03
Filing Date
2025-10-29
Publication Date
2026-09-01

Smart Images

  • Figure TWG2TA001074527_001
    Figure TWG2TA001074527_001
  • Figure TWG2TA001074527_002
    Figure TWG2TA001074527_002
  • Figure TWG2TA001074527_003
    Figure TWG2TA001074527_003
Patent Text Reader

Abstract

The present invention relates to methods of treating B-cell lymphomas, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering an anti-CD20 / anti-CD3 bispecific antibody (e.g., glofitamab) and in combination with one or more anti-CD20 antibodies (e.g., obinutuzumab and / or rituximab) and one or more chemotherapeutic agents selected from ifosfamide, carboplatin, and / or etoposide.
Need to check novelty before this filing date? Find Prior Art